Bevacizumab Offers No Benefit for Newly Diagnosed Glioblastoma

Published June 7, 2013

Bevacizumab Offers No Benefit for Newly Diagnosed Glioblastoma

Filed under: drug treatment centers in virginia

Bevacizumab recently received approval in the second-line (recurrent disease) setting, and we knew some physicians were already giving the drug as a frontline therapy — even with virtually no data to support that decision. … Florida; David Schiff, M …
Read more on Newswise (press release)

Salomonella outbreak in US from imported cucumbers

Filed under: drug treatment centers in virginia

The illness usually lasts 4 to 7 days, and most persons recover without treatment. However, in some … Following the association of the infections with cucumbers imported from Mexico, the U.S. Food and Drug Administration placed the companies Cardenas …
Read more on DigitalJournal.com

Test helps target glioblastoma patients most likely to benefit from bevacizumab

Filed under: drug treatment centers in virginia

This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the addition of bevacizumab to standard chemoradiation and maintenance temozolomide in treating newly diagnosed glioblastoma. Half of the participants received …
Read more on EurekAlert (press release)